1

ELN-EHA SWG annual report 2016

Chronic Myeloid Leukemia (CML)

Introduction and focus of the European LeukemiaNet (ELN)-EHA Scientific

Working Group (SWG) (WP4)

ELN-EHA SWG for CML focuses on promoting knowledge on treatment and

outcome of CML.

ELN-EHA SWG leadership

Chair

Prof. Rüdiger Hehlmann

Medizinsche Fakultät Mannheim, University Heidelberg

Pettenkoferstraße 22

68169 Mannheim

Phone: +49 621 3836931

E-Mail: R.Hehlmann@urz.uni-heidelberg.de

ELN-EHA SWG structure

Board members are:

Prof. Michele Baccarani, Bologna, Italy

Prof. François Guilhot, Poitiers, France

Prof. Andreas Hochhaus, Jena, Germany

Prof. Bengt Simonsson, Uppsala, Sweden

Conflict of interests of the board

Chair:

Prof. R. Hehlmann - research support Novartis, consultation BMS

Board members

Prof. M. Baccarani - Honoraria for consultancy, and speaker fee, from ARIAD,

BMS, Novartis and Pfizer.

Prof. F. Guilhot – Consultant for Celgene and Pfizer, research grant from

Novartis and BMS.

2

Prof. A. Hochhaus – research grant Novartis BMS, Pfizer and ARIAD,

consulting Novartis, BMS, ARIAD and Pfizer, honoraria Novartis BMS, Pfizer

and ARIAD

Prof. B. Simonsson – has no conflict of interest to report.

The group wrote and published a book on CML, Springer 2016 (Editor R.

Hehlmann), 15 chapters authored, or coauthored, by members of the SWG.

List of members

“Annexes: Membership list (excel file)”

ELN-EHA SWG for CML comprises 146 members in 37 countries.

Meetings (educational and scientific)

In 2016, the SWG-CML had two meetings:

- In Mannheim on Feb. 2 and 3 in the context of the 13. Annual ELN-Symposium

- In Copenhagen on June 9 in the context of the 21st EHA-Congress

Lectures and other scientific activities 2016 (Prof. Hehlmann)

1. ELN-Jahressymposium, Mannheim, 2.-3.2.2016

Coordination and Chair

3

2. Deutscher Krebskongress, Berlin, 24.-27.2.2016

Chair KNL-Session and Lecture, 25.2.2016: „Personalisiertes Management

der CML“

3. Casinogesellschaft Weinheim, Weinheim 3.3.2016

Lecture: „Leukämie“

4. Hematology Forum, Samara, 18.-19.3.2016

Lecture:” Can we cure CML? Management recommendations on behalf of

ELN”

5. Symposium: Stem Cell Therapy – Facts and Myths, Heidelberg, 31.3.-

2.4.2016

Lecture, 1.4.2016: “Cure of CML: Are we there yet?”

6. III Congress of Russian Hematologists, Moskau, 14.-16.4.2016

Lecture: “CML – where do we stand in 2016?”

7. EICML, Versailles, 12.-14-5.2016

Chair and Lecture, 13.5.2016: “Preliminary evidence of ACA as indicators

of blast increase.”

8. 5th International Conference - Leukemia 2016, Santa Margherita, 20.5.2016

John Goldman Lecture: “Cure of CML – any time soon?”

9. ELN-EHA-SWG Meeting on CML, 10.6.2016

10. Meeting of the Spanish CML-Group, Madrid, 23.6.2016

Lecture: “The German CML Group: the obstacles you have faced and how

you succeeded”

11. X Raisa Gorbacheva memorial Meeting, St. Petersburg, 22.-25.9.2016

Chair and Lecture, 23.9.2016: “HCT or drug treatment: Perspectives of a

cure of CML”

12. Eurasian Hematology Congress Istanbul, 12.-16.10.2016

Lecture, 13.10.2016: “Is 400 mg OD the correct dosage of Imatinib?”

13. DGHO, Leipzig, 14.-18.10.2016

Chair, KNL-educational session on leukemia, 18.10.2016

14. Educational Meeting: MPNs for Practitioners, New York, 3.-5.11.2016

Chair 4.11.2016

Lecture, 4.11.2016: “Discontinuation of Imatinib: Is it Safe?”

Meet the Professor 5.11.2016: „Cure of CML – anytime soon?‟

15. Advances in Hematology and clinical practice, Bergamo, 11.-12.11.2016

Debate: “Treatment of CML in practice: which strategies?”

Lecture, 11.11.2016: "Strategy for survival"

16. Post-ASH, Estancia, La Jolla, 6.-7.12.2016

Lecture: „The relevance of patients´ and transplantation risks for

successful outcome of HCT: final results of CML-Study IIIA”

List of publications on CML 2016: Chair Rüdiger Hehlmann (1-12)

4

Hehlmann R, Saußele S, Voskanyan A, Silver RT. Management of CML-blast crisis. Best Pract Res Clin Haematol. 2016 Sep;29(3):295-307. doi: 10.1016/j.beha.2016.10.005. Review.

Varghese J, Holz C, Neuhaus P, Bernardi M, Boehm A, Ganser A, Gore S, Heaney M, Hochhaus A, Hofmann WK, Krug U, Müller-Tidow C, Smith A, Weltermann A, de Witte T, Hehlmann R, Dugas M. Key Data Elements in Myeloid Leukemia. Stud Health Technol Inform. 2016;228:282-6.

Hoffmann VS, Baccarani M, Hasford J, Castagnetti F, Di Raimondo F, Casado LF, Turkina A, Zackova D, Ossenkoppele G, Zaritskey A, Höglund M, Simonsson B, Indrak K, Sninska Z, Sacha T, Clark R, Bogdanovic A, Hellmann A, Griskevicius L, Schubert-Fritschle G, Sertic D, Guilhot J, Lejniece S, Zupan I, Burgstaller S, Koskenvesa P, Everaus H, Costeas P, Lindoerfer D, Rosti G, Saussele S, Hochhaus A, Hehlmann R. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.Leukemia. 2017 Mar;31(3):593-601. doi: 10.1038/leu.2016.246.

Hehlmann R. Innovation in hematology. Perspectives: CML 2016.Haematologica. 2016 Jun;101(6):657-9. doi: 10.3324/haematol.2016.142877. No abstract available.

Mughal TI, Abdel-Wahab O, Rampal R, Mesa R, Koschmieder S, Levine R, Hehlmann R, Saglio G, Barbui T, Van Etten RA. Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms. Leuk Lymphoma. 2016 Jul;57(7):1517-26. doi: 10.1080/10428194.2016.1185783.

Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A, Kim DW, Kim TD, Khoury HJ, Le Coutre P, Mayer J, Milojkovic D, Porkka K, Rea D, Rosti G, Saussele S, Hehlmann R, Clark RE. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016 Aug;30(8):1648-71. doi: 10.1038/leu.2016.104. Review.

Kossak-Roth U, Saußele S, Aul C, Büchner T, Döhner H, Dugas M, Ehninger G, Ganser A, Giagounidis A, Gökbuget N, Griesshammer M, Hasford J, Heuser M, Hiddemann W, Hochhaus A, Hoelzer D, Niederwieser D, Reiter A, Röllig C, Hehlmann R. [Leukemia research in Germany: the Competence Network Acute and Chronic Leukemias]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016 Apr;59(4):444-53. doi: 10.1007/s00103-016-2315-x. Review. German.

Padula WV, Larson RA, Dusetzina SB, Apperley JF, Hehlmann R, Baccarani M, Eigendorff E, Guilhot J, Guilhot F, Hehlmann R, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Saussele S, Schiffer CA, Silver RT, Simonsson B, Conti RM. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. J Natl Cancer Inst. 2016 Mar 4;108(7). pii: djw003. doi: 10.1093/jnci/djw003.

Miranda MB, Lauseker M, Kraus MP, Proetel U, Hanfstein B, Fabarius A, Baerlocher GM, Heim D, Hossfeld DK, Kolb HJ, Krause SW, Nerl C, Brümmendorf TH, Verbeek W, Fauser AA, Prümmer O, Neben K, Hess U, Mahlberg R, Plöger C, Flasshove M, Rendenbach B, Hofmann WK, Müller MC, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R, Saußele S. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. Leukemia. 2016 Jun;30(6):1255-62. doi: 10.1038/leu.2016.20.

Hehlmann R. CML - we are not there yet. Eur J Haematol. 2016 Aug;97(2):107. doi: 10.1111/ejh.12712. No abstract available.

5

Gratwohl A, Pfirrmann M, Zander A, Kröger N, Beelen D, Novotny J, Nerl C, Scheid C, Spiekermann K, Mayer J, Sayer HG, Falge C, Bunjes D, Döhner H, Ganser A, Schmidt-Wolf I, Schwerdtfeger R, Baurmann H, Kuse R, Schmitz N, Wehmeier A, Fischer JT, Ho AD, Wilhelm M, Goebeler ME, Lindemann HW, Bormann M, Hertenstein B, Schlimok G, Baerlocher GM, Aul C, Pfreundschuh M, Fabian M, Staib P, Edinger M, Schatz M, Fauser A, Arnold R, Kindler T, Wulf G, Rosselet A, Hellmann A, Schäfer E, Prümmer O, Schenk M, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Büsche G, Haferlach C, Schnittger S, Müller MC, Reiter A, Berger U, Saußele S, Hochhaus A, Hehlmann R; SAKK.; German CML Study Group.. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment.Leukemia. 2016 Mar;30(3):562-9. doi: 10.1038/leu.2015.281.

Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G, Hoffmann VS, Castagnetti F, Hasford J, Hehlmann R, Simonsson B. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016 Jan;30(1):48-56. doi: 10.1038/leu.2015.261.

List of publications on CML 2016: Board member Michele Baccarani (1-17)

Castagnetti F.......and Baccarani M. Nilotinib 300 mg twice daily: an academic

single-arm study of newly diagnosed chronic phase chronic myeloid leukemia

patients. Haematologica 2016;101:1200-1207.

Padula WV.....Baccarani M, et al. Cost-effectiveness of tyrosine kinasse

inhibitor treatment strategies for chronic myeloid leukemia in chronic phase

after generic entry of imatinib in the United States. J Natl Cancer Inst

2016;108(7):

Cortes JE..... Baccarani M, et al. Final 5-year results of DASISION. The

Dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia

patients trial. J Clin Oncol 2016

Efficace F.... Baccarani M, et al. Psychological well-being and social support in

chronic myeloid leukemia patients receiving lifelong targeted therapies.

Support Care Cancer 2016

Steegmann JL......Baccarani M, et al. European LeukemiaNet

recommendations for the management and avoidance of adverse events of

treatment in chronic myeloid leukemia. Leukemia 2016;30:1648-1671.

Baccarani M et al. A review and un update of European LeukaemiaNet

recommendations for the management of chronic myeloid leukaemia. In

Hehlmann R, Ed, Chronic Myeloid Leukemia, Hematologic Malignancies,

Springer, 2016, DOI 10.1007/978-3-31933198-0 4

Hoffmann VS, Baccarani M et al. Treatment and outcome of 2904 patients

from the EUTOS population-based registry. Leukemia 2016

Castagnetti F......and Baccarani M. A population-based study of chronic

myeloid leukemia patients treated with imatinib in first-line. Am J Hematol

2017;92:82-87.

6

Rosti G......and Baccarani M. Tyrosine kinase inhibiotrs in chronic myeloid

leukaemia: which, when, for whom? Nature Med 2016

doi:10.1038/nrclinonc.2016.139

Breccia M....and Baccarani M. Identification and management of

cardiovascular risk in chronic myeloid leukaemia patients candidate to

ponatinib: an expert opinion. Ann Hematol 2016 DOI 10.1007/s00277-016-

2820-x

Dorer DJ.....Baccarani M, et al. Impact of dose intensity of ponatinib on

selected adverse events: multivariate analyses from a pooled population of

clinical trial patients. Leuk Res 2016;48:84-91.

Abruzzese E.....and Baccarani M. Management of pregnant chronic myeloid

leukemia patients. Exp Rev Hematol 2016;9(8):781-791.

Malagola M. Papayannidis C, and Baccarani M. Tyrosine kinase inhibitors in

Ph+ acute lymphoblastic leukaemia: facts and perspectives. Ann Hematol

2016 DOI 10.1007/s00277-016-2617-y

Pfirmann M.....and Baccarani M. No influence of BCR-ABL1 transcript types

e13a2 and e14a2 on long term survival. results in 1494 patients with chronic

myeloid leukemia treated with imatinib. J Cancer Res Clin Oncol 2016 DOI

10.1007/s00432-016-2321-2

Luatti S......Baccarani M, et al. Cryptic BCR-ABL fusion gene as variant

rearrangement in chronic myeloid leukemia: molecula cytogenetic

charcaterization and influence on TKIs therapy. Oncotarget 2016

Pfirrmann M, Baccarani M, et al. Prognosis of long-term survival considering

disease-specific death in patients with chronic myeloid leukemia. Leukemia

2016;30:48-56.

Gugliotta G ...... and Baccarani M. Rotation of nilotinib and imatinib for first-line

treatment of chronic phase chronic myeloid leukemia. Am J Hematol

2016;91:617-622.

List of activities 2016 (Michele Baccarani)

Chairmen and speakers at

- GIMEMA CML WP general meeting, Rome, 8-9.02.16

- Educational Workshop in Panama, 3-5.03.16

- Educational Workshop in Romania, 8-9 04.16

- Nordic Meeting of Young Hematologists, Copenhagen 15-16.04.16

- Educational Workshop in Bologna, Italy, 18-19.04.16

- Workshop on Ponatinib, London 23.04.16

- International Meeting on New Drugs, Bologna 9-10.04.16

7

- Annual Meeting of the European Investigators in CML, Versailles, 13-14.04.16

- Annual Meeeting of the European Haematology Association, Copenhagen, 10-

12.05.16

- National Meeting of the GIMEMA CML WP, Rome, 6.07.16

- Educational Meeting in Barcelona, 2-3.09.16

- Educational Workshop in Brescia, 19.09.16

- CML GIMEMA Preceptorship in Bologna, 21-22.09.16

- International Meeting in Rome, 23-24.09.16

- Educational Workshop in Bari, 6-7.10.16

- CML GIMEMA Preceptorship in Bologna 13-14.10.16

- GIMEMA-HOVON Workshop in Amsterdam 24-25.10.16

- Educational Workshop in Thessaloniki, Greece, 3-4.11.16

- International Meeting in Bergamo, Italy, 11-12.11.16

- GIMEMA CML WP Workshop in Pollenzo, Italy. 18-19..11.16

- Eucational workshop in Treviso, Italy, 25-26.11.16

List of trials

Ongoing

- GIMEMA CML 0912, observational, nilotinib first-line

- GIMEMA CML 1113, observational, dasatinib first-line

- GIMEMA CML 1012, observational, pregnancy

- GIMEMA LEONIDAS, quality of life

- OPTkIMA, intermittent TKI treatment in optimal responders

Newly started.

GIMEMA CML 1415 SUSTRENIM, First-line, prospective randomized study of

nilotinib vs imatinib with switch to nilotinib in non-optimal responders

GIMEMA CML 1315 OPUS, a phase 2 single arm study of low dose ponatinib in

second line

8

GIMEMA CML 1516 BEST, a phase 2 single arm study of low dose bosutinib in

second line, in the elderly

List of grants

None

List of activities (Francois Guilhot)

1. Meetings and presentation 13th Annual symposium of the European Leukemia Net ; Mannheim ,

Germany : Feb 2-3 , 2016

24th Meeting of the European Investigators on CML Versailles, France, May,

12-14, 2016

18th Annual John John Goldman Conference on Chronic myeloid

leukemia Houston , USA: September 15-18 2016 . Keynote lecture:

Biomarkers for prognostic evaluation: how to identify the best

Social and public activities Director of the Clinical Research Centre CIC 1402 INSERM: (2008-…) at

the University Hospital of Poitiers

Member of the of the scientists council of the Medical School of University

of Poitou-Charentes area

President of the haematological section of the National Council of French

Physicians

Ongoing trials and grants A phase III prospective randomized comparison of imatinib in combination with

Peg-Interferon-alpha2a (Peg-IFN2a) or cytarabine (ara-C) versus imatinib

alone: STI571 ProspectIve RandomIzed Trial: SPIRIT; grant :

€1.300,000; ID n° PHRC 2301 Funding organization: French Minister of

Health;

Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase

Chronic Myeloid Leukemia ; grant : € 250,000; ID n° CA 180-502 Funding

organization: BMS;

candidate therapies in combination or sequentially with tyrosine kinase

inhibitors in chronic phase chronic myelogenous leukaemia (cp-cml) patients

in complete cytogenetic response without achieving a deep molecular

response: an adaptive trial based on a drop loser design: ACTIW trial grant :

€450,000; ID n° PHRC 2014 Funding organization: French Minister of Health.

List of publications on CML 2016: Board member Francois Guilhot (1-9)

Rousselot P, Prost S, Guilhot J, Roy L, Etienne G, Legros L, Charbonnier

A, Coiteux V, Cony-Makhoul P, Huguet F, Cayssials E, Cayuela JM,

Relouzat F, Delord M, Bruzzoni-Giovanelli H, Morisset L, Mahon FX,

Guilhot F, Leboulch P; French CML Group.. Pioglitazone together with

9

imatinib in chronic myeloid leukemia: A proof of concept study. Cancer.

2016 Dec 27.

Cayssials E, Guilhot F. Beyond tyrosine kinase inhibitors: Combinations

and other agents.Best Pract Res Clin Haematol. 2016 Sep;29(3):271-283.

Review.

Basbous S, Levescot A, Piccirilli N, Brizard F, Guilhot F, Roy L,

Bourmeyster N, Gombert JM, Herbelin A. The Rho-ROCK pathway as a

new pathological mechanism of innate immune subversion in chronic

myeloid leukaemia. J Pathol. 2016 Nov;240(3):262-268.

Guilhot F. Cytogenetics in CML: more important than you think Blood.

2016 Jun 2;127(22):2661-2.

Khoury HJ, Goldberg SL, Mauro MJ, Stone RM, Deininger MW, Bradley-

Garelik MB, Mohamed H, Guilhot F. Cross-Intolerance With Dasatinib

Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid

Leukemia. Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):341-349

Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S,

Etienne G, Nicolini FE, le Coutre P, Clark RE, Stenke L, Andorsky D,

Oehler V, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M,

Cortes JE, Guilhot F, Hochhaus A, Hughes T, Kantarjian HM, Shah NP,

Talpaz M, Deininger MW; EPIC investigators.. Ponatinib versus imatinib for

newly diagnosed chronic myeloid leukaemia: an international, randomised,

open-label, phase 3 trial. Lancet Oncol. 2016 May;17(5):612-21.

Padula WV, Larson RA, Dusetzina SB, Apperley JF, Hehlmann R,

Baccarani M, Eigendorff E, Guilhot J, Guilhot F, Hehlmann R, Mahon FX,

Martinelli G, Mayer J, Müller MC, Niederwieser D, Saussele S, Schiffer CA,

Silver RT, Simonsson B, Conti RM. Cost-effectiveness of Tyrosine Kinase

Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic

Phase After Generic Entry of Imatinib in the United States. J Natl Cancer

Inst. 2016 Mar 4;108(7).

Puyade M, Defossez G, Guilhot F, Ingrand P. Multiple myeloma: the

quality of care is linked to geographical and organisational determinants. A

study in a French registry. Eur J Cancer Care (Engl). 2016 Sep;25(5):855-

63.

Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C,

Beyne-Rauzy O, Banos A, Guerci-Bresler A, Wickenhauser S, Caillot D,

Laribi K, De Renzis B, Bordessoule D, Gardin C, Slama B, Sanhes L,

Gruson B, Cony-Makhoul P, Chouffi B, Salanoubat C, Benramdane R,

Legros L, Wattel E, Tertian G, Bouabdallah K, Guilhot F, Taksin AL,

Cheze S, Maloum K, Nimuboma S, Soussain C, Isnard F, Gyan E, Petit R,

Lejeune J, Sardnal V, Renneville A, Preudhomme C, Fontenay M, Fenaux

P, Dreyfus F. Lenalidomide with or without erythropoietin in transfusion-

dependent erythropoiesis-stimulating agent-refractory lower-risk MDS

without 5q deletion. Leukemia. 2016 Apr;30(4):897-905.

10

List of activities (Andreas Hochhaus)

Meeting of the German CML Alliance. 250 participants. Weimar, April 8-9,

2016.

Annual Meeting of the German, Austrian and Swiss Societies of

Hematology and Medical Oncology, Leipzig, October 14-18, 2016

List of trials (ongoing, newly started, completed in 2016)

See attached

List of grants obtained

Start of EUTOS2016 (2 year private public partnership - 12 participants in

7 European countries, Novartis, 2016-18)

Model-based optimisation and individualisation of treatment strategies in haematology” (“HaematoOPT”, BMBF, 2014-17)

List of publications on CML 2016: Board member Andreas Hochhaus (1-17)

Ben-Batalla I, Erdmann R, Jørgensen H, Mitchell R, Ernst T, von Amsberg

G, Schafhausen P, Velthaus JL, Rankin S, Clark RE, Koschmieder S,

Schultze A, Mitra S, Vandenberghe P, Brümmendorf TH, Carmeliet P,

Hochhaus A, Pantel K, Bokemeyer C, Helgason GV, Holyoake TL, Loges

S. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-

Sensitive and -Resistant Chronic Myeloid Leukemia. ClinCancer Res. 2016

Nov 17. doi: 10.1158/1078-0432.CCR-16-1930. [Epub ahead of print]

PubMed PMID: 27856601.

Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, Shah

NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A.

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib

Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J Clin

Oncol. 2016 Jul 10;34(20):2333-40. doi: 10.1200/JCO.2015.64.8899.

PubMed PMID: 27217448; PubMedCentral PMCID: PMC5118045.

Shah NP, Rousselot P, Schiffer C, Rea D, Cortes JE, Milone J, Mohamed

H, Healey D, Kantarjian H, Hochhaus A, Saglio G. Dasatinib in imatinib-

resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-

year follow-up of study CA180-034. Am J Hematol. 2016 Sep;91(9):869-

74. doi: 10.1002/ajh.24423.PubMed PMID: 27192969; PubMed Central

PMCID: PMC5094534.

11

Cross NC, Hochhaus A. Deep molecular response in chronic myeloid

leukemia. Leukemia. 2016 Jul;30(7):1632. doi: 10.1038/leu.2016.78.

PubMed PMID: 27174492.

Saußele S, Richter J, Hochhaus A, Mahon FX. The concept of treatment-

free remission in chronic myeloid leukemia. Leukemia. 2016

Aug;30(8):1638-47. doi:10.1038/leu.2016.115. Review. PubMed PMID:

27133824; PubMed Central PMCID:PMC4980559.

Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V,

Hochhaus A, Kim DW, Kim TD, Khoury HJ, Le Coutre P, Mayer J,

Milojkovic D, Porkka K, Rea D, Rosti G, Saussele S, Hehlmann R, Clark

RE. European LeukemiaNet recommendations for the management and

avoidance of adverse events of treatment in chronic myeloid leukaemia.

Leukemia. 2016 Aug;30(8):1648-71. doi:10.1038/leu.2016.104. Review.

PubMed PMID: 27121688; PubMed Central PMCID:PMC4991363.

Cross NC, White HE, Ernst T, Welden L, Dietz C, Saglio G, Mahon FX,

Wong CC, Zheng D, Wong S, Wang SS, Akiki S, Albano F, Andrikovics H,

Anwar J, Balatzenko G, Bendit I, Beveridge J, Boeckx N, Cerveira N,

Cheng SM, Colomer D, Czurda S,Daraio F, Dulucq S, Eggen L, El Housni

H, Gerrard G, Gniot M, Izzo B, Jacquin D, Janssen JJ, Jeromin S, Jurcek

T, Kim DW, Machova-Polakova K, Martinez-Lopez J,

McBean M, Mesanovic S, Mitterbauer-Hohendanner G, Mobtaker H,

Mozziconacci MJ, Pajič T, Pallisgaard N, Panagiotidis P, Press RD, Qin

YZ, Radich J, Sacha T, Touloumenidou T, Waits P, Wilkinson E, Zadro R,

Müller MC, Hochhaus A, Branford S. Development and evaluation of a

secondary reference panel for BCR-ABL1quantification on the International

Scale. Leukemia. 2016 Sep;30(9):1844-52. doi:10.1038/leu.2016.90.

PubMed PMID: 27109508; PubMed Central PMCID: PMC5240017.

Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S,

Etienne G, Nicolini FE, le Coutre P, Clark RE, Stenke L, Andorsky D,

Oehler V, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M,

Cortes JE, Guilhot F, Hochhaus A, Hughes T, Kantarjian HM, Shah NP,

Talpaz M, Deininger MW; EPIC investigators..Ponatinib versus imatinib for

newly diagnosed chronic myeloid leukaemia: an international, randomised,

open-label, phase 3 trial. Lancet Oncol. 2016 May;17(5):612-21. doi:

10.1016/S1470-2045(16)00080-2. PubMed PMID: 27083332.

Thielen N, Richter J, Baldauf M, Barbany G, Fioretos T, Giles F, Gjertsen

BT, Hochhaus A, Schuurhuis GJ, Sopper S, Stenke L, Thunberg S, Wolf D,

Ossenkoppele G, Porkka K, Janssen J, Mustjoki S. Leukemic Stem Cell

Quantification in Newly Diagnosed Patients With Chronic Myeloid

Leukemia Predicts Response to Nilotinib Therapy. Clin Cancer Res. 2016

Aug 15;22(16):4030-8. doi:10.1158/1078-0432.CCR-15-2791. PubMed

PMID: 27006491.

Schiffer CA, Cortes JE, Hochhaus A, Saglio G, le Coutre P, Porkka K,

Mustjoki S, Mohamed H, Shah NP. Lymphocytosis after treatment with

dasatinib in chronic myeloid leukemia: Effects on response and toxicity.

12

Cancer. 2016 May 1;122(9):1398-407. doi: 10.1002/cncr.29933. PubMed

PMID: 26998677; PubMed Central PMCID: PMC5071708.

Kossak-Roth U, Saußele S, Aul C, Büchner T, Döhner H, Dugas M,

Ehninger G, Ganser A, Giagounidis A, Gökbuget N, Griesshammer M,

Hasford J, Heuser M, Hiddemann W, Hochhaus A, Hoelzer D,

Niederwieser D, Reiter A, Röllig C, Hehlmann R. [Leukemia research in

Germany: the Competence Network Acute and Chronic Leukemias].

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016

Apr;59(4):444-53. doi: 10.1007/s00103-016-2315-x. Review. German.

PubMed PMID: 26979719.

Miranda MB, Lauseker M, Kraus MP, Proetel U, Hanfstein B, Fabarius A,

Baerlocher GM, Heim D, Hossfeld DK, Kolb HJ, Krause SW, Nerl C,

Brümmendorf TH, Verbeek W, Fauser AA, Prümmer O, Neben K, Hess U,

Mahlberg R, Plöger C, Flasshove M, Rendenbach B, Hofmann WK, Müller

MC, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R, Saußele S.

Secondary malignancies in chronic myeloid leukemia patients after

imatinib-based treatment: long-term observation in CML Study IV.

Leukemia. 2016 Jun;30(6):1255-62. doi: 10.1038/leu.2016.20. PubMed

PMID:26859076; PubMed Central PMCID: PMC4895174.

Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le

Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae

H, Donohue B, Deng W, Dalal D, Menssen HD, Kantarjian HM. Long-term

benefits and risks of frontline nilotinib vs imatinib for chronic myeloid

leukemia in chronic phase: 5-year update of the randomized ENESTnd

trial. Leukemia. 2016 May;30(5):1044-54. doi:10.1038/leu.2016.5. PubMed

PMID: 26837842; PubMed Central PMCID: PMC4858585.

Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, de Wit

TD, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T,

Rodeghiero F, Salles G, Schuringa JJ; EHA Roadmap for European

Hematology Research.. The European Hematology Association Roadmap

for European Hematology Research: a consensus document.

Haematologica. 2016 Feb;101(2):115-208.

doi:10.3324/haematol.2015.136739. PubMed PMID: 26819058; PubMed

Central PMCID:PMC4938336.

Deininger MW, Hodgson JG, Shah NP, Cortes JE, Kim DW, Nicolini FE,

Talpaz M, Baccarani M, Müller MC, Li J, Parker WT, Lustgarten S,

Clackson T, Haluska FG, Guilhot F, Kantarjian HM, Soverini S, Hochhaus

A, Hughes TP, Rivera VM, Branford S. Compound mutations in BCR-ABL1

are not major drivers of primary or secondary resistance to ponatinib in

CP-CML patients. Blood. 2016 Feb 11;127(6):703-12. doi: 10.1182/blood-

2015-08-660977. PubMed PMID: 26603839; PubMed Central PMCID:

PMC4760131.

Gratwohl A, Pfirrmann M, Zander A, Kröger N, Beelen D, Novotny J, Nerl

C, Scheid C, Spiekermann K, Mayer J, Sayer HG, Falge C, Bunjes D,

Döhner H, Ganser A, Schmidt-Wolf I, Schwerdtfeger R, Baurmann H, Kuse

13

R, Schmitz N, Wehmeier A, Fischer JT, Ho AD, Wilhelm M, Goebeler ME,

Lindemann HW, Bormann M, Hertenstein B, Schlimok G, Baerlocher GM,

Aul C, Pfreundschuh M, Fabian M, Staib P, Edinger M, Schatz M, Fauser

A, Arnold R, Kindler T, Wulf G, Rosselet A, Hellmann A, Schäfer E,

Prümmer O, Schenk M, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ,

Büsche G, Haferlach C, Schnittger S, Müller MC, Reiter A, Berger U,

Saußele S,Hochhaus A, Hehlmann R; SAKK.; German CML Study Group..

Long-term outcome ofpatients with newly diagnosed chronic myeloid

leukemia: a randomized comparison of stem cell transplantation with drug

treatment. Leukemia. 2016 Mar;30(3):562-9.doi: 10.1038/leu.2015.281.

PubMed PMID: 26464170; PubMed Central PMCID:PMC4777774.

Hochhaus A, Rosti G, Cross NC, Steegmann JL, le Coutre P,

Ossenkoppele G, Petrov L, Masszi T, Hellmann A, Griskevicius L, Wiktor-

Jedrzejczak W, Rea D, Coriu D, Brümmendorf TH, Porkka K, Saglio G,

Gastl G, Müller MC, Schuld P, Di Matteo P, Pellegrino A, Dezzani L,

Mahon FX, Baccarani M, Giles FJ. Frontline nilotinib in patients with

chronic myeloid leukemia in chronic phase: results from the European

ENEST1st study. Leukemia. 2016 Jan;30(1):57-64.

doi:10.1038/leu.2015.270. PubMed PMID: 26437782; PubMed Central

PMCID: PMC4705425.

List of publications on CML 2016: Board member Bengt Simonsson (1-2)

Söderlund S, Christiansson L, Persson I, Hjorth-Hansen H, Richter J, Simonsson B, Mustjoki S, Olsson-Strömberg U, Loskog A. Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli.Leuk Res. 2016 Nov;50:95-103. doi: 10.1016/j.leukres.2016.09.019. PMID:27710869

Padula WV, Larson RA, Dusetzina SB, Apperley JF, Hehlmann R, Baccarani M, Eigendorff E, Guilhot J, Guilhot F, Hehlmann R, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Saussele S, Schiffer CA, Silver RT, Simonsson B, Conti RM. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.J Natl Cancer Inst. 2016 Mar 4;108(7). pii: djw003. doi: 10.1093/jnci/djw003. PMID:26944912